Currently in Phase 3 clinical trials and not yet FDA-approved, retatrutide is studied for its ability to amplify energy expenditure beyond what single or dual agonists achieve
400,000 B16-F10 murine melanoma cells were injected into the tail vein of C57BL/6 mice
Design a Robust Experiment: Develop a detailed protocol including control groups, appropriate measurement endpoints, and planned statistical analyses
We also found a significant reduction in the levels of tumor promoter GPs at the end of 4th week during 4-week intermittent fasting (POLK, CD109, CAMP, NIFK, SRGN), and 1 week after 4-week intermittent fasting (CAMP, PLAC1) compared with the levels before 4-week intermittent fasting
It is important not to self-administer or exceed recommended dosages, as improper use can lead to adverse effects